Table 1 TKI launched on market
From: Advances in studies of tyrosine kinase inhibitors and their acquired resistance
| TKI | Time to market | Development company | Target | Application of disease |
|---|---|---|---|---|
| Imatinib | 2001 | Novartis | Abl, PDGFR, SCFR | CML, GIST |
| Gefitinib | 2003 | AstraZeneca | EGFR | NSCLC |
| Nilotinib | 2004 | Novartis | Bcr-Abl, PDGFR | CML |
| Sorafenib | 2005 | Bayer | Raf, VEGFR, PDGER | Advanced RCC |
| Sunitinib | 2006 | Pfizer | PDGFR, VEGFR, | GIST, Advanced RCC |
| Dasatinib | 2006 | Bristol-Myers Squibb | Bcr-Abl, SRC, PDGFR | CML |
| Lapatinib | 2007 | GlaxoSmithKline | EGFR | Breast cancer |
| Pazopanib | 2009 | GlaxoSmithKline | VEGFR, PDGFR, FGFR | Advanced RCC,STS,NSCLC |
| Crizotinib | 2011 | Pfizer | ALK | NSCLC |
| Ruxolitinib | 2011 | Novartis | JAK1, JAK2 | myelofibrosis |
| vandetanib | 2011 | AstraZeneca | VEGFR, EGFR | Advanced Thyroid cancer |
| Axitinib | 2012 | Pfizer | VEGFR | Advanced RCC |
| Bosutinib | 2012 | Wyeth | Abl, SRC | CML |
| Afatinib | 2013 | Boehringer Ingelheim | EGFR | NSCLC |
| Erlotinib | 2013 | Roche | EGFR | NSCLC |
| Ceritinib | 2014 | Novartis | ALK | NSCLC |
| Osimertinib | 2015 | AstraZeneca | EGFR | NSCLC |
| Lenvatinib | 2015 | Eisai | VEGFR | DTC |
| Alectinib | 2015 | Roche | ALK | NSCLC |
| Regorafenib | 2017 | Bayer | VEGFR, EGFR | HCC, CRC,GIST |
| Neratinib | 2017 | Puma | HER2 | Breast cancer |
| Brigatinib | 2017 | Ariad | ALK | NSCLC |
